Unknown

Dataset Information

Genomic analysis unlocks the potential of denosumab as a targeted therapy for Crohn's disease.


ABSTRACT: Crohn's disease (CD) is a chronic, relapsing inflammatory disorder of the gastrointestinal tract with limited curative therapies. Genomic drug repurposing offers a rapid strategy to identify existing drugs that could be redirected to treat CD. We retrieved 1,333 CD-associated single-nucleotide polymorphisms from the GWAS Catalog and expanded these to 15,590 variants using linkage disequilibrium analysis in HaploReg. Fourteen layers of functional annotation prioritized 45 high-confidence risk genes. Drug-gene interactions were screened against DGIdb, and tissue expression patterns were assessed using GTEx bulk RNA-seq data. Cellular associations were explored via HuBMAP network analysis. Denosumab, an FDA-approved Receptor Activator of NF-κB Ligand (RANKL) inhibitor, exhibited the highest i

SUBMITTER: Pranata R 

PROVIDER: S-EPMC12749831 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature